BACKGROUND: In the present study, the prognostic impact of minimal residual disease during treatment on time to progression and overall survival was analyzed prospectively in patients with mantle cell lymphoma treated on the Cancer and Leukemia Group B 59909 clinical trial. DESIGN AND METHODS: Peripheral blood and bone marrow samples were collected during different phases of the Cancer and Leukemia Group B 59909 study for minimal residual disease analysis. Minimal residual disease status was determined by quantitative polymerase chain reaction of IgH and/or BCL-1/JH gene rearrangement. Correlation of minimal residual disease status with time to progression and overall survival was determined. In multivariable analysis, minimal residual disease, and other risk factors were correlated with time to progression. RESULTS: Thirty-nine patients had evaluable, sequential peripheral blood and bone marrow samples for minimal residual disease analysis. Using peripheral blood monitoring, 18 of 39 (46%) achieved molecular remission following induction therapy. The molecular remission rate increased from 46 to 74% after one course of intensification therapy. Twelve of 21 minimal residual disease positive patients (57%) progressed within three years of follow up compared to 4 of 18 (22%) molecular remission patients (P=0.049). Detection of minimal residual disease following induction therapy predicted disease progression with a hazard ratio of 3.7 (P=0.016). The 3-year probability of time to progression among those who were in molecular remission after induction chemotherapy was 82% compared to 48% in patients with detectable minimal residual disease. The prediction of time to progression by post-induction minimal residual disease was independent of other prognostic factors in multivariable analysis. CONCLUSIONS: Detection of minimal residual disease following induction immunochemotherapy was an independent predictor of time to progression following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma.
BACKGROUND: In the present study, the prognostic impact of minimal residual disease during treatment on time to progression and overall survival was analyzed prospectively in patients with mantle cell lymphoma treated on the Cancer and Leukemia Group B 59909 clinical trial. DESIGN AND METHODS: Peripheral blood and bone marrow samples were collected during different phases of the Cancer and Leukemia Group B 59909 study for minimal residual disease analysis. Minimal residual disease status was determined by quantitative polymerase chain reaction of IgH and/or BCL-1/JH gene rearrangement. Correlation of minimal residual disease status with time to progression and overall survival was determined. In multivariable analysis, minimal residual disease, and other risk factors were correlated with time to progression. RESULTS: Thirty-nine patients had evaluable, sequential peripheral blood and bone marrow samples for minimal residual disease analysis. Using peripheral blood monitoring, 18 of 39 (46%) achieved molecular remission following induction therapy. The molecular remission rate increased from 46 to 74% after one course of intensification therapy. Twelve of 21 minimal residual disease positive patients (57%) progressed within three years of follow up compared to 4 of 18 (22%) molecular remission patients (P=0.049). Detection of minimal residual disease following induction therapy predicted disease progression with a hazard ratio of 3.7 (P=0.016). The 3-year probability of time to progression among those who were in molecular remission after induction chemotherapy was 82% compared to 48% in patients with detectable minimal residual disease. The prediction of time to progression by post-induction minimal residual disease was independent of other prognostic factors in multivariable analysis. CONCLUSIONS: Detection of minimal residual disease following induction immunochemotherapy was an independent predictor of time to progression following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma.
Authors: Martin Dreyling; Georg Lenz; Eva Hoster; Achiel Van Hoof; Christian Gisselbrecht; Rudolf Schmits; Bernd Metzner; Lorenz Truemper; Marcel Reiser; Hjalmar Steinhauer; Jean-Michel Boiron; Marc A Boogaerts; Ali Aldaoud; Vittorio Silingardi; Hanneke C Kluin-Nelemans; Joerg Hasford; Reza Parwaresch; Michael Unterhalt; Wolfgang Hiddemann Journal: Blood Date: 2004-12-09 Impact factor: 22.113
Authors: Jorge E Romaguera; Luis Fayad; Maria A Rodriguez; Kristine R Broglio; Frederick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Andreas H Sarris; Nam H Dang; Michael Wang; Virginia Beasley; L Jeffrey Medeiros; Ruth L Katz; Harish Gagneja; Barry I Samuels; Terry L Smith; Fernando F Cabanillas Journal: J Clin Oncol Date: 2005-09-06 Impact factor: 44.544
Authors: Gordon Cook; Graeme M Smith; Keiren Kirkland; Julia Lee; Rachel Pearce; Kirsty Thomson; Emma Morris; Kim Orchard; Simon Rule; Nigel Russell; Charles Craddock; David I Marks Journal: Biol Blood Marrow Transplant Date: 2010-04-24 Impact factor: 5.742
Authors: A S Freedman; D Neuberg; P Mauch; R J Soiffer; K C Anderson; D C Fisher; R Schlossman; E P Alyea; T Takvorian; H Jallow; C Kuhlman; J Ritz; L M Nadler; J G Gribben Journal: Blood Date: 1999-11-15 Impact factor: 22.113
Authors: M Magni; M Di Nicola; L Devizzi; P Matteucci; F Lombardi; L Gandola; F Ravagnani; R Giardini; G Dastoli; C Tarella; A Pileri; G Bonadonna; A M Gianni Journal: Blood Date: 2000-08-01 Impact factor: 22.113
Authors: N S Andersen; J W Donovan; J S Borus; C M Poor; D Neuberg; J C Aster; L M Nadler; A S Freedman; J G Gribben Journal: Blood Date: 1997-11-15 Impact factor: 22.113
Authors: J M Vose; P J Bierman; D D Weisenburger; J C Lynch; Y Bociek; W C Chan; T C Greiner; J O Armitage Journal: Biol Blood Marrow Transplant Date: 2000 Impact factor: 5.742
Authors: I F Khouri; J Romaguera; H Kantarjian; J L Palmer; W C Pugh; M Korbling; F Hagemeister; B Samuels; A Rodriguez; S Giralt; A Younes; D Przepiorka; D Claxton; F Cabanillas; R Champlin Journal: J Clin Oncol Date: 1998-12 Impact factor: 44.544
Authors: Stephen E Spurgeon; Brian G Till; Peter Martin; Andre H Goy; Martin P Dreyling; Ajay K Gopal; Michael LeBlanc; John P Leonard; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; Brad S Kahl; Mitchell R Smith Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Erik Magnusson; Qing Cao; Michael A Linden; Jerry Frolich; Vidhu Anand; Linda J Burns; Veronika Bachanova Journal: Clin Lymphoma Myeloma Leuk Date: 2013-11-15
Authors: Robert W Chen; Hongli Li; Steven H Bernstein; Samir Kahwash; Lisa M Rimsza; Stephen J Forman; Louis Constine; Thomas C Shea; Amanda F Cashen; Kristie A Blum; Timothy S Fenske; Paul M Barr; Tycel Phillips; Michael Leblanc; Richard I Fisher; Bruce D Cheson; Sonali M Smith; Malek Faham; Jennifer Wilkins; John P Leonard; Brad S Kahl; Jonathan W Friedberg Journal: Br J Haematol Date: 2016-12-19 Impact factor: 6.998
Authors: Lawrence D Kaplan; Matthew J Maurer; Wendy Stock; Nancy L Bartlett; Noreen Fulton; Adam Pettinger; John C Byrd; Kristie A Blum; Ann S LaCasce; Eric D Hsi; Yi Tian Liu; David W Scott; David Hurd; Amy S Ruppert; Francisco Hernandez-Ilizaliturri; John P Leonard; Bruce D Cheson Journal: Am J Hematol Date: 2020-04-06 Impact factor: 10.047
Authors: Andrew J Cowan; Philip A Stevenson; Ryan D Cassaday; Solomon A Graf; Jonathan R Fromm; David Wu; Leona A Holmberg; Brian G Till; Thomas R Chauncey; Stephen D Smith; Mary Philip; Johnnie J Orozco; Andrei R Shustov; Damian J Green; Edward N Libby; William I Bensinger; Mazyar Shadman; David G Maloney; Oliver W Press; Ajay K Gopal Journal: Biol Blood Marrow Transplant Date: 2015-09-05 Impact factor: 5.742
Authors: Jia Ruan; Peter Martin; Paul Christos; Leandro Cerchietti; Wayne Tam; Bijal Shah; Stephen J Schuster; Amelyn Rodriguez; David Hyman; Maria Nieves Calvo-Vidal; Sonali M Smith; Jakub Svoboda; Richard R Furman; Morton Coleman; John P Leonard Journal: Blood Date: 2018-09-04 Impact factor: 22.113